CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
In a double-blinded fashion, 250 mg CANNAXR cream +1 moredevice
Likely dose
In a double-blinded fashion, 250 mg CANNAXR creamfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05279495
NCT05279495N/ACompleted
CompareCT.gov

Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers

MINO Labs, LLC·interventional·Posted Mar 15, 2022·Updated May 8, 2025

In Brief

A clinical study evaluating In a double-blinded fashion, 250 mg CANNAXR cream and Topical VEHICLE cream for Photoaging. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Ultraviolet light A (UVA) causes oxidization of guanine to mutagenic 8-Oxoguanine (8-OxoG) and the most frequent and best characterized mutation in mitochondrial DNA (mtDNA), a deletion of 4,977 base pairs, called the "common deletion", a marker of photoaging.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhotoaging
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedMar 15, 2022
Enrollment StartJan 15, 2023
Primary CompletionApr 1, 2023
Study CompletionMay 15, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.3 years ago

Interventions

In a double-blinded fashion, 250 mg CANNAXR creamdevice

Determining the Efficacy of topically applied CANNAXR cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg TOPICAL CBD CANNAXR Cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks

Topical VEHICLE creamdevice

Determining the Efficacy of topically applied VEHICLE cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks